Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Transforming the Treatment of GBM

Raphael Nir, PhD and Michael Briggs, PhD – Biologics Investors

Woodland Pharmaceuticals

Executive Summary – October 2014

• Glioblastoma is an orphan disease with a poor outcome and a high unmet need due to its diffuse nature and high rate of recurrence

• Woodland Pharmaceuticals holds novel biologic insights, derived from its proprietary assays / methods, including mechanisms and methods to halt tumor growth and block metastasis

–Woodland has identified novel combined mechanisms lethal to tumors

–Drug combinations that reflect these mechanisms are delivered to the brain by a patent-protected formulation

–Intellectual property has been filed

• Additional compounds that fit the combination requirements, along with emerging delivery technologies, are the subject of an active business development licensing effort

• The Woodland team consists of functional experts with significant pharmaceutical experience. The team is executing a work plan to file an IND for the treatment of GBM patients within 24 months (by YE2016)

• The team is currently evaluating options to support this work plan

For additional information please contact:

Michael Briggs

617-416-2522

mbriggs@woodlandpharma.com